Epilepsy research · 2026
Intrathecal dexamethasone in FIRES.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Foong Wai Dic, Tan Zhibin, Hassan Sarah Hasnor Abu, Tan You Jiang
Аннотация
BACKGROUND: New-onset refractory status epilepticus (NORSE) and its subset, febrile infection-related epilepsy syndrome (FIRES), are rare but severe neurological disorders. Conventional systemic immunotherapies such as intravenous methylprednisolone, intravenous immunoglobulin, and biologic agents often yield suboptimal outcomes. Intrathecal dexamethasone (IT-DEX) has emerged as a potential therapeutic option. Here, we review existing literature on the use of IT-DEX in patients with FIRES.
METHODS: Searches of PubMed and Google Scholar (1 January 2010-31 December 2025) was performed, and reports of NORSE/FIRES treated with IT-DEX were reviewed. Demographical data, ancillary test findings, cytokine profiles, IT-DEX regimen, and treatment outcomes were extracted and analysed.
RESULTS: Two case series and six case reports were identified, comprising 24 patients with FIRES. The median age was 7 years (IQR 6-12). Prior to receiving IT-DEX, all were treated with systemic immunotherapy and anaesthetic agents. IT-DEX was initiated a median of 19.5 days (IQR 10.5-39.5) from onset, with a median dose and cumulative dose of 0.20 mg/kg/dose (IQR 0.19-0.25) and 1.12 mg/kg (IQR 0.90-1.29) respectively, administered at a median of 72-hour intervals. Patients received a median of 5 doses (IQR 4.5-6). No adverse events were reported. 87.5% showed clinical improvement, and anaesthetic agents were discontinued in nearly all. 39.1% achieved favourable functional outcomes, especially in those receiving cumulative doses of ≥ 1 mg/kg (p = 0.048). However, improvement in cytokine levels and the time to commencing IT-DEX did not influence treatment outcomes.
CONCLUSION: IT-DEX may represent a promising therapeutic option for FIRES, particularly in children and adolescents. Our findings provide preliminary evidence supporting its potential use, with administration at 72-hour intervals to a cumulative dose of 1 mg/kg emerging as a potentially reasonable approach. However, further studies are required to determine its optimal dosing, safety and efficacy.
METHODS: Searches of PubMed and Google Scholar (1 January 2010-31 December 2025) was performed, and reports of NORSE/FIRES treated with IT-DEX were reviewed. Demographical data, ancillary test findings, cytokine profiles, IT-DEX regimen, and treatment outcomes were extracted and analysed.
RESULTS: Two case series and six case reports were identified, comprising 24 patients with FIRES. The median age was 7 years (IQR 6-12). Prior to receiving IT-DEX, all were treated with systemic immunotherapy and anaesthetic agents. IT-DEX was initiated a median of 19.5 days (IQR 10.5-39.5) from onset, with a median dose and cumulative dose of 0.20 mg/kg/dose (IQR 0.19-0.25) and 1.12 mg/kg (IQR 0.90-1.29) respectively, administered at a median of 72-hour intervals. Patients received a median of 5 doses (IQR 4.5-6). No adverse events were reported. 87.5% showed clinical improvement, and anaesthetic agents were discontinued in nearly all. 39.1% achieved favourable functional outcomes, especially in those receiving cumulative doses of ≥ 1 mg/kg (p = 0.048). However, improvement in cytokine levels and the time to commencing IT-DEX did not influence treatment outcomes.
CONCLUSION: IT-DEX may represent a promising therapeutic option for FIRES, particularly in children and adolescents. Our findings provide preliminary evidence supporting its potential use, with administration at 72-hour intervals to a cumulative dose of 1 mg/kg emerging as a potentially reasonable approach. However, further studies are required to determine its optimal dosing, safety and efficacy.